



FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015

CONTENTS

Independent Auditors' Report.....	1
Statements of Financial Position.....	2
Statements of Activities	3-4
Statements of Cash Flows	5
Statements of Functional Expenses	6-7
Notes to the Financial Statements	8-16

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of the
Arthritis National Research Foundation

We have audited the accompanying financial statements of the Arthritis National Research Foundation (a California nonprofit corporation), which comprise the statements of financial position as of March 31, 2016 and 2015, and the related statements of activities, cash flows, and functional expenses for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Arthritis National Research Foundation as of March 31, 2016 and 2015, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Windes, Inc.

Long Beach, California
September 7, 2016

ARTHRITIS NATIONAL RESEARCH FOUNDATION

STATEMENTS OF FINANCIAL POSITION

ASSETS

	March 31,	
	2016	2015
ASSETS		
Cash and cash equivalents	\$ 1,065,255	\$ 457,052
Accrued interest receivable	13,014	13,014
Investments	6,893,716	8,130,333
Deposits	2,432	
Note receivable	56,415	56,415
TOTAL ASSETS	\$ 8,030,832	\$ 8,656,814

LIABILITIES AND NET ASSETS

LIABILITIES		
Accounts payable	\$ 5,104	\$ 5,104
Grants payable	50,000	
TOTAL LIABILITIES	55,104	5,104
COMMITMENTS (Note 5)		
NET ASSETS		
Unrestricted		
Undesignated	4,186,287	4,575,987
Board designated endowment	3,422,313	4,065,437
Total Unrestricted	7,608,600	8,641,424
Temporarily restricted	356,842	
Permanently restricted	10,286	10,286
	7,975,728	8,651,710
TOTAL LIABILITIES AND NET ASSETS	\$ 8,030,832	\$ 8,656,814

The accompanying notes are an integral part of these financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED MARCH 31, 2016**

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
SUPPORT AND REVENUE				
Public support				
Contributions and bequests	\$ 855,689	\$ 356,842		\$ 1,212,531
Total Public Support	<u>855,689</u>	<u>356,842</u>		<u>1,212,531</u>
Investment return				
Interest income	53,246			53,246
Dividend income	102,984			102,984
Gain on sale of investments	371,926			371,926
Unrealized loss on investments	(614,508)			(614,508)
Total Investment Return	<u>(86,352)</u>			<u>(86,352)</u>
TOTAL SUPPORT AND REVENUE	<u>769,337</u>	<u>356,842</u>		<u>1,126,179</u>
EXPENSES				
Program Services				
Research	1,440,782			1,440,782
Education	224,973			224,973
Total Program Services	<u>1,665,755</u>			<u>1,665,755</u>
Supporting Services				
Management and general	99,379			99,379
Fundraising	37,027			37,027
Total Supporting Services	<u>136,406</u>			<u>136,406</u>
TOTAL EXPENSES	<u>1,802,161</u>			<u>1,802,161</u>
CHANGE IN NET ASSETS	(1,032,824)	356,842		(675,982)
NET ASSETS AT BEGINNING OF YEAR	<u>8,641,424</u>	<u>None</u>	<u>\$ 10,286</u>	<u>8,651,710</u>
NET ASSETS AT END OF YEAR	<u>\$ 7,608,600</u>	<u>\$ 356,842</u>	<u>\$ 10,286</u>	<u>\$ 7,975,728</u>

The accompanying notes are an integral part of these financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**STATEMENT OF ACTIVITIES
FOR THE YEAR ENDED MARCH 31, 2015**

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
SUPPORT AND REVENUE				
Public support				
Contributions and bequests	\$ 1,055,132			\$ 1,055,132
Total Public Support	<u>1,055,132</u>			<u>1,055,132</u>
Investment return				
Interest income	56,846			56,846
Dividend income	105,159			105,159
Gain on sale of investments	225,718			225,718
Unrealized gain on investments	128,869			128,869
Total Investment Return	<u>516,592</u>			<u>516,592</u>
TOTAL SUPPORT AND REVENUE	<u>1,571,724</u>			<u>1,571,724</u>
EXPENSES				
Program Services				
Research	1,188,519			1,188,519
Education	174,461			174,461
Total Program Services	<u>1,362,980</u>			<u>1,362,980</u>
Supporting Services				
Management and general	100,141			100,141
Fundraising	32,783			32,783
Total Supporting Services	<u>132,924</u>			<u>132,924</u>
TOTAL EXPENSES	<u>1,495,904</u>			<u>1,495,904</u>
CHANGE IN NET ASSETS	75,820			75,820
NET ASSETS AT BEGINNING OF YEAR	<u>8,565,604</u>		\$ 10,286	<u>8,575,890</u>
NET ASSETS AT END OF YEAR	<u>\$ 8,641,424</u>	<u>None</u>	<u>\$ 10,286</u>	<u>\$ 8,651,710</u>

The accompanying notes are an integral part of these financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

STATEMENTS OF CASH FLOWS

	For the Year Ended March 31,	
	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ (675,982)	\$ 75,820
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Gain on sale of investments	(371,926)	(225,718)
Unrealized (gain) loss on investments	614,508	(128,869)
Stock donations received	(3,123)	(9,108)
Increase in:		
Deposits	(2,432)	
Accounts payable		587
Grants payable	50,000	
Net Cash Used In Operating Activities	(388,955)	(287,288)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments	(969,996)	(1,145,945)
Proceeds from sale of investments	1,967,154	1,118,717
Net Cash Provided By (Used In) Investing Activities	997,158	(27,228)
NET CHANGE IN CASH AND CASH EQUIVALENTS	608,203	(314,516)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	457,052	771,568
CASH AND CASH EQUIVALENTS AT END OF YEAR	\$ 1,065,255	\$ 457,052

The accompanying notes are an integral part of these financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED MARCH 31, 2016**

	<u>Program Services</u>			<u>Supporting Services</u>			<u>Total Expenses</u>
	<u>Research</u>	<u>Education</u>	<u>Total</u>	<u>Management and General</u>	<u>Fund-raising</u>	<u>Total</u>	
Research grants	\$ 1,281,281		\$ 1,281,281				\$ 1,281,281
Grants for professional meetings	27,125		27,125				27,125
Awareness program	3,309	\$ 40,348	43,657	\$ 255	\$ 9,231	\$ 9,486	53,143
Salaries - Executive							
Director	47,417	51,333	98,750	11,583	9,667	21,250	120,000
Salaries - other	35,386	38,177	73,563	10,111	5,600	15,711	89,274
Payroll tax	6,099	6,414	12,513	1,716	988	2,704	15,217
Health insurance	11,267	10,113	21,380	2,113	1,384	3,497	24,877
Office rent/parking	5,733	9,952	15,685	5,820	2,219	8,039	23,724
Telephone and internet	505	1,343	1,848	823	17	840	2,688
Website	1,405	11,231	12,636	3,226	300	3,526	16,162
Insurance	740	781	1,521	5,228	117	5,345	6,866
Investment fees				19,340		19,340	19,340
Advertising	2,550	10,493	13,043	4,000	442	4,442	17,485
Workplace campaign		11,728	11,728	100	4,573	4,673	16,401
Office expenses	1,129	15,587	16,716	13,771	1,776	15,547	32,263
Professional fees	9,500	10,840	20,340	19,567	75	19,642	39,982
Recognition	801	198	999	164		164	1,163
Printing		6,313	6,313	1,495	638	2,133	8,446
Board meetings	6,535	122	6,657	67		67	6,724
	<u>\$ 1,440,782</u>	<u>\$ 224,973</u>	<u>\$ 1,665,755</u>	<u>\$ 99,379</u>	<u>\$ 37,027</u>	<u>\$ 136,406</u>	<u>\$ 1,802,161</u>

The accompanying notes are an integral part of these financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED MARCH 31, 2015**

	<u>Program Services</u>			<u>Supporting Services</u>			<u>Total Expenses</u>
	<u>Research</u>	<u>Education</u>	<u>Total</u>	<u>Management and General</u>	<u>Fund-raising</u>	<u>Total</u>	
Research grants	\$ 1,024,562		\$ 1,024,562				\$ 1,024,562
Grants for professional meetings	15,000	\$ 556	15,556				15,556
Awareness program	250	12,908	13,158	\$ 3,212	\$ 7,833	\$ 11,045	24,203
Salaries - Executive							
Director	51,617	47,798	99,415	11,828	8,657	20,485	119,900
Salaries - other	39,030	38,147	77,177	10,349	6,308	16,657	93,834
Payroll tax	7,029	6,507	13,536	1,731	1,106	2,837	16,373
Health insurance	9,651	9,677	19,328	2,986	1,802	4,788	24,116
Office rent/parking	5,924	7,081	13,005	5,178	1,398	6,576	19,581
Telephone and internet	453	1,229	1,682	729	175	904	2,586
Website	7,450	11,025	18,475	5,418	500	5,918	24,393
Insurance	861	805	1,666	4,683	140	4,823	6,489
Investment fees				19,371		19,371	19,371
Advertising	1,708	11,787	13,495	764	208	972	14,467
Workplace campaign		2,418	2,418	150	2,304	2,454	4,872
Office expenses	600	10,003	10,603	10,423	1,197	11,620	22,223
Professional fees	20,600	6,880	27,480	20,800	1,006	21,806	49,286
Recognition	1,869	179	2,048	708	49	757	2,805
Dues and subscriptions		300	300	248		248	548
Printing	262	7,161	7,423	1,241	100	1,341	8,764
Board meetings	1,653		1,653	322		322	1,975
	<u>\$ 1,188,519</u>	<u>\$ 174,461</u>	<u>\$ 1,362,980</u>	<u>\$ 100,141</u>	<u>\$ 32,783</u>	<u>\$ 132,924</u>	<u>\$ 1,495,904</u>

The accompanying notes are an integral part of these financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS MARCH 31, 2016 AND 2015

NOTE 1 – Summary of Significant Accounting Policies

Organization

The Arthritis National Research Foundation (“Foundation”) was incorporated on May 2, 1952 as a California nonprofit corporation. The Foundation was organized to provide financial support for the study of prevention, treatment, and cure of arthritis and other rheumatic diseases.

Basis of Presentation of Financial Statements

The Foundation is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted, temporarily restricted, and permanently restricted net assets.

Unrestricted Net Assets – Net assets that are not subject to donor-imposed restrictions.

Temporarily Restricted Net Assets – Net assets subject to donor-imposed stipulations that may or will be met either by actions of the Foundation or the passage of time. As the restrictions are satisfied, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the accompanying statements of activities as net assets released from restrictions.

Permanently Restricted Net Assets – Net assets subject to donor-imposed restrictions that the corpus be invested in perpetuity and only the income be made available for program operations in accordance with donor restrictions. Such income generally includes interest, dividends, and realized and unrealized earnings from the corpus.

Use of Estimates and Assumptions

Management uses estimates and assumptions in preparing financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were assumed in preparing the financial statements.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015**

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Concentration of Credit Risk – Cash

At March 31, 2016 and throughout the year, the Foundation had cash balances in financial institutions in excess of federally insured limits. The Foundation has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

Cash and Cash Equivalents

For purposes of the statements of cash flows, the Foundation considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

Investments

The Foundation carries investments in marketable securities with readily determinable fair values and all investments in debt securities at their fair values in the statements of financial position. The valuation of marketable securities is based upon quoted market prices. Unrealized and realized gains and losses are included in the change in net assets in the accompanying statements of activities.

The Foundation's investments are exposed to various risks, such as market and credit risks. Due to the level of risk associated with such investments and the level of uncertainty related to changes in the value of such investments, it is at least reasonably possible that changes in risks in the near term could materially affect investment balances and the amounts reported in the financial statements.

Contributions

Contributions, including endowment gifts and pledges, are recognized as support in the period received or pledged. Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. Amortization of the discount to present value is included in contribution revenue. Conditional promises to give are not included as support until the conditions are substantially met.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS MARCH 31, 2016 AND 2015

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Contributions (Continued)

All contributions are considered to be available for unrestricted use unless specifically restricted by the donor. Contributions received that are designated for future periods or restricted by the donor for specific purposes are reported as temporarily restricted or permanently restricted support that increases those net asset classes. When a donor's stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statements of activities as net assets released from restrictions. Donor-restricted contributions whose restrictions are met in the same reporting period are reported as unrestricted support. Permanently restricted contributions and net assets have restrictions stipulated by the donor that the corpus be invested in perpetuity and only the income be made available for operations.

Legacies and Bequests

The Foundation has been named as beneficiary in a number of bequests. Bequests are not recognized as support until all of the following conditions are met: the demise of the testator, the amount of the bequest is known, the Foundation is certain that, based on the estate's net assets, the amount bequeathed is realizable, and the probate court has declared the will valid.

Allocation of Functional Expenses

The costs of providing the various programs and supporting services have been summarized on a functional basis in the statements of activities and functional expenses. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

Advertising Expenses

The Foundation charges advertising costs to expense as they are incurred. These costs are included in the accompanying statement of functional expenses.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS MARCH 31, 2016 AND 2015

NOTE 1 – Summary of Significant Accounting Policies (Continued)

Income Taxes

The Foundation has received tax-exempt status from the Internal Revenue Service and California Franchise Tax Board under Section 501(c)(3) of the Internal Revenue Code and Section 23701(d) of the Revenue and Taxation Code, respectively. Accordingly, no provision for income taxes is included in the accompanying financial statements.

The Foundation recognizes the financial statement benefit of tax positions, such as its filing status as tax-exempt, only after determining that the relevant tax authority would more likely than not sustain the position following an audit. The Foundation is subject to potential income tax audits on open tax years by any taxing jurisdiction in which it operates. The statute of limitations for federal purposes is three years and for California purposes is four years.

Contributions In-Kind

Contributions of donated noncash assets are recorded at fair value in the period received. Contributions of donated services that create or enhance nonfinancial assets or that require specialized skills and are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation, are recorded at fair value in the period received.

The Foundation received no in-kind support during the years ended March 31, 2016 and 2015.

Concentrations – Contributions and Bequests

For the year ended March 31, 2016, approximately 39% of contributions and bequests were from two donors. For the year ended March 31, 2015, approximately 42% of contributions and bequests were from one donor.

Reclassification

Certain amounts in the 2015 financial statements have been reclassified to conform to the 2016 financial statement presentation.

Subsequent Events

The Foundation's management has evaluated subsequent events from the statement of financial position date through September 7, 2016, the date the financial statements were available to be issued for the year ended March 31, 2016, and determined that there were no other items to disclose.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015**

NOTE 2 – Investments and Fair Value Hierarchy

The Foundation uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine the fair value disclosures. The fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for the Foundation’s various financial instruments. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including discount rates and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the instrument. The Foundation groups its assets and liabilities measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Foundation has the ability to access at the measurement date.
- Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs for the asset or liability.

The following table presents assets that are measured at fair value on a recurring basis at March 31, 2016 and 2015:

<u>March 31, 2016</u>	<u>Fair Value</u>	<u>Fair Value Measurements at Reporting Date</u>		
		<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Mutual Funds	\$ 2,653,811	\$ 2,653,811		
Domestic Stocks	2,696,294	2,696,294		
Corporate Bonds	1,393,261		\$ 1,393,261	
Foreign Bonds	150,350		150,350	
	<u>\$ 6,893,716</u>	<u>\$ 5,350,105</u>	<u>\$ 1,543,611</u>	<u>None</u>

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015**

NOTE 2 – Investments and Fair Value Hierarchy (Continued)

<u>March 31, 2015</u>	<u>Fair Value</u>	<u>Fair Value Measurements at Reporting Date</u>		
		<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Mutual Funds	\$ 3,184,549	\$ 3,184,549		
Domestic Stocks	2,658,793	2,658,793		
Corporate Bonds	1,478,311		\$ 1,478,311	
Foreign Bonds	154,635		154,635	
Certificates of Deposit	<u>654,045</u>		<u>654,045</u>	
	<u>\$ 8,130,333</u>	<u>\$ 5,843,342</u>	<u>\$ 2,286,991</u>	<u>None</u>

NOTE 3 – Note Receivable

The note receivable is due from the trust of a donor, with interest due annually at 5%. The note will be paid in full to the Foundation on the date of termination of the owner's estate. The outstanding balance of the note at March 31, 2016 and 2015 is \$56,415.

NOTE 4 – Restrictions on Net Assets

Net assets were restricted by donors or designated by the Foundation as follows:

	<u>March 31,</u>	
	<u>2016</u>	<u>2015</u>
Unrestricted net assets:		
Undesignated	\$ 4,186,287	\$ 4,575,987
Board designated endowment	<u>3,422,313</u>	<u>4,065,437</u>
Total Unrestricted Net Assets	<u>7,608,600</u>	<u>8,641,424</u>
Temporary restricted net assets:		
Restricted for Ankylosing spondylitis research	<u>356,842</u>	<u>None</u>
Total Temporary Restricted Net Assets:	<u>356,842</u>	<u>None</u>
Permanently restricted net assets:		
Endowment fund	<u>10,286</u>	<u>10,286</u>
Total Permanently Restricted Net Assets	<u>10,286</u>	<u>10,286</u>
Total Net Assets	<u>\$ 7,975,728</u>	<u>\$ 8,651,710</u>

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015**

NOTE 5 – Commitments

The Foundation leases commercial office space and office equipment under various terms through March 2021 or on a month-to-month basis. The terms of the office space lease provide for payment of minimum annual rentals. Office and equipment rental expense for the years ended March 31, 2016 and 2015 was \$27,682 and \$22,045, respectively.

Future minimum lease payments under these operating lease agreements are as follows:

<u>Year Ending March 31,</u>	
2017	\$ 30,888
2018	30,888
2019	30,888
2020	30,888
2021	<u>21,160</u>
	<u>\$ 144,712</u>

NOTE 6 – Endowment Funds

The Foundation’s endowment consists of one donor-restricted contribution of \$10,286 and a board-designated fund established to generate return which is sufficient to meet the current and expected future financial requirements of the Foundation. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The Foundation’s management and investment of donor-endowment funds is subject to the Uniform Prudent Management of Institutional Funds Act (UPMIFA). The Foundation has interpreted California’s enacted version of UPMIFA as requiring the preservation of the fair value of the original gift as of the date of the gift of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Foundation classifies as permanently restricted net assets: (a) the original value of the gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the Foundation’s management in a manner consistent with the standard of prudence prescribed by UPMIFA. Board-designated endowment funds are reported as unrestricted net assets.

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015**

NOTE 6 – Endowment Funds (Continued)

Spending Policy for Endowment Funds

The income generated by the board-designated endowment fund, including dividends, interest and realized gains, may be appropriated annually to fund general operations and grant making. Earnings in excess of grant expenditures and operations may be used for expanding knowledge and support of the Foundation.

Investment Policy for Endowment Funds

The Foundation utilizes investment policies for endowment assets that attempt to provide a predictable stream of funding of its programs and operations while seeking to maintain the purchasing power of the endowment assets. Specifically, over a market cycle of three to five years, the total return should exceed the Consumer Price Index by 4% annually and should average at least 6% annually. The Foundation targets a diversified asset allocation that places greater emphasis on fixed income and equity-based investments.

Net changes in endowment funds for the years ended March 31, 2016 and 2015 were as follows:

<u>March 31, 2016</u>	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 4,065,437		\$ 10,286	\$ 4,075,723
Investment return:				
Investment income	55,672	\$ 166		55,838
Net depreciation (realized and unrealized)	(148,796)			(148,796)
Total investment return	(93,124)	166		(92,958)
Contributions				
Board-designated transfers	250,000			250,000
Appropriation of endowment assets for expenditure	(800,000)	(166)		(800,166)
Endowment net assets, end of year	\$ 3,422,313	None	\$ 10,286	\$ 3,432,599

ARTHRITIS NATIONAL RESEARCH FOUNDATION

**NOTES TO THE FINANCIAL STATEMENTS
MARCH 31, 2016 AND 2015**

NOTE 6 – Endowment Funds (Continued)

<u>March 31, 2015</u>	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Endowment net assets, beginning of year	\$ 4,390,806	None	\$ 10,286	\$ 4,401,092
Investment return:				
Investment income	65,059	\$ 438		65,497
Net appreciation (realized and unrealized)	<u>208,572</u>			<u>208,572</u>
Total investment return	<u>273,631</u>	<u>438</u>		<u>274,069</u>
Contributions				
Board-designated transfers	<u>101,000</u>			<u>101,000</u>
Appropriation of endowment assets for expenditure	<u>(700,000)</u>	<u>(438)</u>		<u>(700,438)</u>
Endowment net assets, end of year	<u>\$ 4,065,437</u>	<u>None</u>	<u>\$ 10,286</u>	<u>\$ 4,075,723</u>